Clinical trial · Interventional
SEgmentectomy Versus Lobectomy in T1C Non-Small Cell Lung Cancer (SELTIC)
Segmentectomy Versus Lobectomy in Clinical T1c Non-Small Cell Lung Cancer: A Non-Inferiority Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to investigate the role of segmentectomy in clinical T1c (2-3 cm) non-small cell lung cancer (NSCLC). The main questions we aim to answer are: 1. Is segmentectomy non-inferior to lobectomy in cT1c NSCLC in terms of overall and recurrence free survival? 2. What are the mortality and morbidity rates of segmentectomy compared to lobectomy? Researchers will compare segmentectomy and lobectomy in terms of overall and recurrence free survival. Participants will: * Undergo either pulmonary lobectomy or segmentectomy with mediastinal nodal dissection * Be followed up with a chest CT in every 3 months in first year, every 6 months in second year and every year for following 3 years
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lobectomy | Procedure | — | UNRESOLVED |
| Segmentectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Segmentectomy
- description
- Pulmonary anatomic segmentectomy with mediastinal nodal dissection
- interventionNames
- Procedure: Segmentectomy
- type
- ACTIVE_COMPARATOR
- label
- Lobectomy
- description
- Pulmonary lobectomy with mediastinal nodal dissection
- interventionNames
- Procedure: Lobectomy
Primary outcomes (1)
- measure
- Survival Survival
- timeFrame
- 5 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical T1c NSCLC * Parenchymal nodule \>2 cm in diameter * Parenchymal nodule ≤3 cm in diameter * Consolidation / Tumor Rate (CTR) ≥ 0.50 * Definitive pathological diagnosis of NSCLC preoperative or intraoperatively * No evidence of distant metastasis * No evidence of N2 disease * Adequate pulmonary functions for lobectomy or segmentectomy Exclusion Criteria: * Pure GGO lesions * Pathologic diagnosis other than NSCLC * Technically not suitable for simple or complex segmentectomy, or lobectomy * Evidence of distant metastasis * Pathologically confirmed N2 or N3 disease * Major comorbidity that precludes surgery * Intraoperative mediastinal nodal dissection of less than 3 lymph node stations * Prior malignancy in five years
References
Publications (0)
Data not yet available